SAN
RAFAEL, Calif., Aug. 29,
2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
(NASDAQ: BMRN) today announced that Brian
Mueller, Executive Vice President, Chief Financial Officer
of BioMarin will present at the 22nd Annual Morgan
Stanley Global Healthcare Conference on Thursday, September 5, 2024, at 7:45 AM PT / 10:45 AM
ET in New York, NY.
An audio webcast of the presentation will be available live. You
can access the webcast at: https://investors.biomarin.com/. An
archived version of the remarks will also be available through the
Company's website for a limited time following the
conference.
About BioMarin
Founded in 1997, BioMarin is a global biotechnology company
dedicated to transforming lives through genetic discovery. The
company develops and commercializes targeted therapies that address
the root cause of the genetic conditions. BioMarin's unparalleled
research and development capabilities have resulted in eight
transformational commercial therapies for patients with rare
genetic disorders. The company's distinctive approach to drug
discovery has produced a diverse pipeline of commercial, clinical,
and pre-clinical candidates that address a significant unmet
medical need, have well-understood biology, and provide an
opportunity to be first-to-market or offer a substantial benefit
over existing treatment options. For additional information, please
visit www.biomarin.com.
|
Contacts:
|
|
|
Investors
|
Media
|
|
Traci McCarty
|
Marni Kottle
|
|
BioMarin Pharmaceutical Inc.
|
BioMarin Pharmaceutical Inc.
|
|
(415) 455-7558
|
650) 374-2803
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-22nd-annual-morgan-stanley-global-healthcare-conference-on-thursday-september-5-at-745-am-pt--1045-am-et-in-new-york-ny-302233312.html
SOURCE BioMarin Pharmaceutical Inc.
